A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

What Was Tested

The trial (phase 2) is built around Eloralintide.

Participation will last about 64 weeks.

It had eight arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

Participants will receive macupatide subcutaneously (SC).

Participants will receive eloralintide SC.

Participants will receive macupatide SC and eloralintide SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 400 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: See Master Protocol CWMM (NCT06143956) for inclusion criteria.

The full record lists 1 inclusion and 5 exclusion criteria; among the exclusions: have type 1 diabetes or type 2 diabetes; have an ongoing history of bradyarrhythmia and/or sinus bradycardia; have a history of acute or chronic pancreatitis.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Eloralintide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Eloralintide.

Those kept unaware of assignments: participant and investigator.

It started in 2026-05-15 with completion listed for 2027-09.

It ran at 40 sites in United States (40).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percent Change from Baseline in Body Weight (time frame: Baseline, Week 36).

It also tracked 5 secondary outcomes, for example Percent Change from Baseline in Body Weight, Change from Baseline in Body Weight and Change from Baseline in Body Mass Index (BMI).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Eloralintide in 400 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.